Back to Results
First PageMeta Content
Cancer organizations / Norwalk /  Connecticut / Bortezomib / Pyrazines / Carfilzomib / Medicine / Oncology / Cancer research


      Cleave  Biosciences  Initiates  Phase  1  Clinical  Trial  of  CB-­‐5083  in   Patients  with  Multiple  Myeloma  
Add to Reading List

Document Date: 2014-09-04 12:51:29


Open Document

File Size: 1,09 MB

Share Result on Facebook

City

Burlingame / CB / /

Company

Cleave Biosciences / /

Country

United States / /

Facility

National Cancer Institute / University of Kansas / California Institute of Technology / Winship Cancer Institute of Emory University / laboratory of Raymond J / The Scripps Research Institute / /

IndustryTerm

protein homeostasis systems / /

MedicalCondition

refractory disease / tumor / cancer / lymphoma / multiple myeloma / tumors / disease / hematologic cancer / solid tumor / U.S. cancer / solid tumors / hematologic malignancies / common blood cancer / relapsed and refractory multiple myeloma / Multiple Myeloma Multiple myeloma / multiple myeloma patients / /

Organization

Emory University / California Institute of Technology / University of Kansas / /

Person

Chou / /

Position

Howard Hughes Medical Institute Investigator / Chief Executive Officer / Director of Translational Research / Professor of Biology / Professor of Hematology / /

ProvinceOrState

Kansas / California / /

Technology

pharmacokinetics / pharmacodynamics / apoptosis / /

URL

www.cleavebio.com / www.clinicaltrials.gov / /

SocialTag